Janus kinase inhibitor treatment improved both subcutaneous and pulmonary sarcoidosis in a patient with glaucoma.

This is the first case to provide significant evidence that JAK inhibitor is an effective treatment for both subcutaneous and pulmonary sarcoidosis, and it is also the first case in which tofacitinib was used in a patient who has a contraindication for corticosteroid therapy.